FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FN1-NNMT

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FN1-NNMT
FusionPDB ID: 30825
FusionGDB2.0 ID: 30825
HgeneTgene
Gene symbol

FN1

NNMT

Gene ID

2335

4837

Gene namefibronectin 1nicotinamide N-methyltransferase
SynonymsCIG|ED-B|FINC|FN|FNZ|GFND|GFND2|LETS|MSF|SMDCF-
Cytomap

2q35

11q23.2

Type of geneprotein-codingprotein-coding
Descriptionfibronectincold-insoluble globulinepididymis secretory sperm binding proteinmigration-stimulating factornicotinamide N-methyltransferase
Modification date2020032920200329
UniProtAcc

P02751

Main function of 5'-partner protein: FUNCTION: Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin (PubMed:3024962, PubMed:3900070, PubMed:3593230, PubMed:7989369). Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape (PubMed:3024962, PubMed:3900070, PubMed:3593230, PubMed:7989369). Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization (By similarity). Participates in the regulation of type I collagen deposition by osteoblasts (By similarity). Acts as a ligand for the LILRB4 receptor, inhibiting FCGR1A/CD64-mediated monocyte activation (PubMed:34089617). {ECO:0000250|UniProtKB:P11276, ECO:0000269|PubMed:3024962, ECO:0000269|PubMed:34089617, ECO:0000269|PubMed:3593230, ECO:0000269|PubMed:3900070, ECO:0000269|PubMed:7989369}.; FUNCTION: [Anastellin]: Binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling. {ECO:0000269|PubMed:11209058, ECO:0000269|PubMed:15665290, ECO:0000269|PubMed:19379667, ECO:0000269|PubMed:8114919}.

P40261

Main function of 5'-partner protein: FUNCTION: Catalyzes the N-methylation of nicotinamide and other pyridines to form pyridinium ions. This activity is important for biotransformation of many drugs and xenobiotic compounds.
Ensembl transtripts involved in fusion geneENST idsENST00000357009, ENST00000323926, 
ENST00000336916, ENST00000345488, 
ENST00000354785, ENST00000356005, 
ENST00000357867, ENST00000359671, 
ENST00000421182, ENST00000432072, 
ENST00000443816, ENST00000446046, 
ENST00000346544, ENST00000426059, 
ENST00000490833, 
ENST00000535401, 
ENST00000541754, ENST00000299964, 
ENST00000535185, ENST00000542647, 
ENST00000545255, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score47 X 49 X 13=299398 X 7 X 6=336
# samples 489
** MAII scorelog2(48/29939*10)=-5.96284781832542
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/336*10)=-1.90046432644909
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: FN1 [Title/Abstract] AND NNMT [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FN1 [Title/Abstract] AND NNMT [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FN1(216232586)-NNMT(114168673), # samples:1
Anticipated loss of major functional domain due to fusion event.FN1-NNMT seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FN1-NNMT seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FN1-NNMT seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FN1-NNMT seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFN1

GO:0001932

regulation of protein phosphorylation

11792823

HgeneFN1

GO:0008284

positive regulation of cell proliferation

25834989

HgeneFN1

GO:0010628

positive regulation of gene expression

25834989

HgeneFN1

GO:0018149

peptide cross-linking

3997886

HgeneFN1

GO:0034446

substrate adhesion-dependent cell spreading

16236823

HgeneFN1

GO:0035987

endodermal cell differentiation

23154389

HgeneFN1

GO:0048146

positive regulation of fibroblast proliferation

25834989

HgeneFN1

GO:0051702

interaction with symbiont

12167537|12421310|19429745

HgeneFN1

GO:0070372

regulation of ERK1 and ERK2 cascade

11792823

HgeneFN1

GO:1901166

neural crest cell migration involved in autonomic nervous system development

26571399

HgeneFN1

GO:1904237

positive regulation of substrate-dependent cell migration, cell attachment to substrate

25834989

HgeneFN1

GO:2001202

negative regulation of transforming growth factor-beta secretion

25834989



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:216232586/chr11:114168673)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FN1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across NNMT (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000421182FN1chr2216232586-ENST00000535401NNMTchr11114168673+802165721072122400
ENST00000357867FN1chr2216232586-ENST00000535401NNMTchr11114168673+783063811170212336
ENST00000323926FN1chr2216232586-ENST00000535401NNMTchr11114168673+864071911178312606
ENST00000336916FN1chr2216232586-ENST00000535401NNMTchr11114168673+836769181175582515
ENST00000354785FN1chr2216232586-ENST00000535401NNMTchr11114168673+8837738811580282637
ENST00000345488FN1chr2216232586-ENST00000535401NNMTchr11114168673+785464051170452344
ENST00000359671FN1chr2216232586-ENST00000535401NNMTchr11114168673+846070111176512546
ENST00000446046FN1chr2216232586-ENST00000535401NNMTchr11114168673+829268431174832490
ENST00000443816FN1chr2216232586-ENST00000535401NNMTchr11114168673+810266531672932425
ENST00000432072FN1chr2216232586-ENST00000535401NNMTchr11114168673+810266531072932427
ENST00000356005FN1chr2216232586-ENST00000535401NNMTchr11114168673+819067411173812456

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000421182ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0007004070.9992995
ENST00000357867ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0006131840.9993868
ENST00000323926ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0009546860.9990453
ENST00000336916ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0009590630.9990409
ENST00000354785ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0004616580.9995384
ENST00000345488ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0005012350.9994987
ENST00000359671ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0004268920.99957305
ENST00000446046ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0007746490.9992254
ENST00000443816ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0006142730.9993857
ENST00000432072ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0007134030.9992866
ENST00000356005ENST00000535401FN1chr2216232586-NNMTchr11114168673+0.0006651290.9993349

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FN1-NNMT

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FN1chr2216232586NNMTchr1111416867363812124GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867364052132GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867365722188GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867366532213GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867366532215GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867367412244GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867368432278GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867369182303GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867370112334GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867371912394GFGSGHFRCDSSNGVKGDLLIDIGSG
FN1chr2216232586NNMTchr1111416867373882425GFGSGHFRCDSSNGVKGDLLIDIGSG

Top

Potential FusionNeoAntigen Information of FN1-NNMT in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FN1-NNMT_216232586_114168673.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FN1-NNMTchr2216232586chr111141686737191HLA-C06:08FRCDSSNGV0.39140.968615
FN1-NNMTchr2216232586chr111141686737191HLA-C06:17FRCDSSNGV0.00180.9784615
FN1-NNMTchr2216232586chr111141686737191HLA-C06:02FRCDSSNGV0.00180.9784615

Top

Potential FusionNeoAntigen Information of FN1-NNMT in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FN1-NNMT_216232586_114168673.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FN1-NNMTchr2216232586chr111141686737191DRB1-0305SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0305GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB1-0338SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0338GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB1-0338FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB1-0338GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB1-0340SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0434SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0434GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB1-0462SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0464SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0466SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0466GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB1-0472SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-0472GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB1-0472GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB1-0474SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-1419SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-1448SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB1-1493SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0101SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0101GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0101FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0101GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0104SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0104GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0104FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0104GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0105SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0105GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0105FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0105GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0108SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0108GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0108FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0108GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0109SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0109GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0109FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0109GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0111SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0111GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0111FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0111GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0112SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0112GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0112FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0112GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0113SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0113GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0113FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0113GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0114SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0114GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0114FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0114GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0202SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0202GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0202GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0205SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0205GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0205GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0209SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0209GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0209GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0209FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0210SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0210GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0210GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0211SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0211GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0212SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0212GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0212GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0212FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0213SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0213GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0213GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0213FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0214SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0214GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0215SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0215GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0216SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0216GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0216GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0216FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0217SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0217GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0217GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0218SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0218GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0218GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0219SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0219GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0219GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0219FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0220SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0220GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0220GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0221SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0221GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0221GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0221FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0222SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0222GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0222GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0222FGSGHFRCDSSNGVK116
FN1-NNMTchr2216232586chr111141686737191DRB3-0223SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0223GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0223GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0225SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0225GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0225GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0303SGHFRCDSSNGVKGD318
FN1-NNMTchr2216232586chr111141686737191DRB3-0303GSGHFRCDSSNGVKG217
FN1-NNMTchr2216232586chr111141686737191DRB3-0303GHFRCDSSNGVKGDL419
FN1-NNMTchr2216232586chr111141686737191DRB3-0303FGSGHFRCDSSNGVK116

Top

Fusion breakpoint peptide structures of FN1-NNMT

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2541FRCDSSNGVKGDLLFN1NNMTchr2216232586chr111141686737191

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FN1-NNMT

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2541FRCDSSNGVKGDLL-7.15543-7.26883
HLA-B14:023BVN2541FRCDSSNGVKGDLL-4.77435-5.80965
HLA-B52:013W392541FRCDSSNGVKGDLL-6.80875-6.92215
HLA-B52:013W392541FRCDSSNGVKGDLL-4.20386-5.23916
HLA-A11:014UQ22541FRCDSSNGVKGDLL-7.5194-8.5547
HLA-A11:014UQ22541FRCDSSNGVKGDLL-6.9601-7.0735
HLA-A24:025HGA2541FRCDSSNGVKGDLL-7.52403-7.63743
HLA-A24:025HGA2541FRCDSSNGVKGDLL-5.82433-6.85963
HLA-B27:056PYJ2541FRCDSSNGVKGDLL-3.28285-4.31815
HLA-B44:053DX82541FRCDSSNGVKGDLL-5.91172-6.94702
HLA-B44:053DX82541FRCDSSNGVKGDLL-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of FN1-NNMT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FN1-NNMTchr2216232586chr11114168673615FRCDSSNGVATTTCAGATGTGATTCATCTAACGGTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
FN1-NNMTchr2216232586chr11114168673116FGSGHFRCDSSNGVKGCTTTGGAAGTGGTCATTTCAGATGTGATTCATCTAACGGTGTGA
FN1-NNMTchr2216232586chr11114168673217GSGHFRCDSSNGVKGTTGGAAGTGGTCATTTCAGATGTGATTCATCTAACGGTGTGAAGG
FN1-NNMTchr2216232586chr11114168673318SGHFRCDSSNGVKGDGAAGTGGTCATTTCAGATGTGATTCATCTAACGGTGTGAAGGGAG
FN1-NNMTchr2216232586chr11114168673419GHFRCDSSNGVKGDLGTGGTCATTTCAGATGTGATTCATCTAACGGTGTGAAGGGAGACC

Top

Information of the samples that have these potential fusion neoantigens of FN1-NNMT

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LIHCFN1-NNMTchr2216232586ENST00000323926chr11114168673ENST00000535401TCGA-DD-A73A-01A

Top

Potential target of CAR-T therapy development for FN1-NNMT

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FN1-NNMT

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FN1-NNMT

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneFN1C0020538Hypertensive disease2CTD_human
HgeneFN1C0432221Spondylometaphyseal dysplasia, 'corner fracture' type2GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFN1C0000786Spontaneous abortion1CTD_human
HgeneFN1C0000822Abortion, Tubal1CTD_human
HgeneFN1C0003504Aortic Valve Insufficiency1CTD_human
HgeneFN1C0006142Malignant neoplasm of breast1CTD_human;UNIPROT
HgeneFN1C0007097Carcinoma1CTD_human
HgeneFN1C0007621Neoplastic Cell Transformation1CTD_human
HgeneFN1C0010346Crohn Disease1CTD_human
HgeneFN1C0011849Diabetes Mellitus1CTD_human
HgeneFN1C0011881Diabetic Nephropathy1CTD_human
HgeneFN1C0017636Glioblastoma1CTD_human
HgeneFN1C0017667Nodular glomerulosclerosis1CTD_human
HgeneFN1C0017668Focal glomerulosclerosis1CTD_human
HgeneFN1C0024667Animal Mammary Neoplasms1CTD_human
HgeneFN1C0024668Mammary Neoplasms, Experimental1CTD_human
HgeneFN1C0027626Neoplasm Invasiveness1CTD_human
HgeneFN1C0034069Pulmonary Fibrosis1CTD_human
HgeneFN1C0041956Ureteral obstruction1CTD_human
HgeneFN1C0085762Alcohol abuse1PSYGENET
HgeneFN1C0086432Hyalinosis, Segmental Glomerular1CTD_human
HgeneFN1C0149721Left Ventricular Hypertrophy1CTD_human
HgeneFN1C0156147Crohn's disease of large bowel1CTD_human
HgeneFN1C0205696Anaplastic carcinoma1CTD_human
HgeneFN1C0205697Carcinoma, Spindle-Cell1CTD_human
HgeneFN1C0205698Undifferentiated carcinoma1CTD_human
HgeneFN1C0205699Carcinomatosis1CTD_human
HgeneFN1C0267380Crohn's disease of the ileum1CTD_human
HgeneFN1C0334588Giant Cell Glioblastoma1CTD_human
HgeneFN1C0345967Malignant mesothelioma1CTD_human
HgeneFN1C0678202Regional enteritis1CTD_human
HgeneFN1C0678222Breast Carcinoma1CTD_human
HgeneFN1C0949272IIeocolitis1CTD_human
HgeneFN1C1257925Mammary Carcinoma, Animal1CTD_human
HgeneFN1C1257931Mammary Neoplasms, Human1CTD_human
HgeneFN1C1458155Mammary Neoplasms1CTD_human
HgeneFN1C1621958Glioblastoma Multiforme1CTD_human
HgeneFN1C1866075GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2 (disorder)1CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFN1C3830362Early Pregnancy Loss1CTD_human
HgeneFN1C3888104Glomerulopathy with fibronectin deposits1CTD_human;ORPHANET
HgeneFN1C4552766Miscarriage1CTD_human
HgeneFN1C4704874Mammary Carcinoma, Human1CTD_human
HgeneFN1C4721507Alveolitis, Fibrosing1CTD_human